RPL22L1 and hepatocellular carcinoma: The present study introduces a robust biomarker, namely RPL22L1, which exhibits elevated expression in LUAD patients, aligning with its increased expression in PRAD, HCC, CRC, KIRC, and OC [7, 9–13].